No profile data available.
aTyr Pharma, Inc. (ATYR) is a healthcare company in the lung treatment pharmaceuticals industry, based in San Diego, United States, with about 58 full-time employees.
It reported revenue of $190,000 for fiscal year 2025, down 19.1% from fiscal year 2024, and net income of -$74.12 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $24.15 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
aTyr Pharma reported $190,000 in revenue for fiscal year 2025, down 19.1% from $235,000 in fiscal year 2024. In Q2 2026 revenue was $0.
$24.15 million as of October 9, 2026.
Listed companies of a similar size in the same industry (lung treatment pharmaceuticals) include Rein Therapeutics Inc. (RNTX), Pliant Therapeutics, Inc. (PLRX), Edesa Biotech, Inc. (EDSA), GRI Bio, Inc. (GRI).